Page 4 - Harvard Bioscience News Today

While Harvard Bioscience, Inc. ( NASDAQ:HBIO ) might not be the most widely known stock at the moment, it received a...

Includes dedicated version for integration with Ponemah data management software from Data Sciences International Expands reach of unique, non-invasive wearable monitoring for pre-clinical research...

GlobalData uncovers the leading innovators in herbal medicinal products for the consumer industry.

Triton Wealth Management PLLC lowered its position in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) by 10.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,288 shares of the medical instruments supplier’s stock after selling 3,454 shares during the quarter. Triton Wealth Management […]

GlobalData uncovers the leading innovators in herbal medicinal products for the consumer industry.

Key Insights The projected fair value for Harvard Bioscience is US$6.54 based on 2 Stage Free Cash Flow to Equity...

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. Harvard Bioscience Stock Performance Shares of HBIO stock remained flat at $4.41 during trading hours on Monday. The stock had a trading volume of 82,500 shares, […]

Major players in the perfusion systems market are Getinge AB , Medtronic plc , LivaNova PLC , Terumo Corporation, Lifeline Scientific Inc., XVIVO Perfusion...

StockNews.com began coverage on shares of Harvard Bioscience (NASDAQ:HBIO – Free Report) in a research report report published on Thursday. The firm issued a buy rating on the medical instruments supplier’s stock. A number of other research firms have also weighed in on HBIO. Benchmark increased their price objective on Harvard Bioscience from $4.00 to […]